[ad_1]
An American pharmaceutical company is closing its manufacturing plant in Baldoyle, threatening the future of 440 jobs there.
Viatris will close the North Dublin plant, which makes generic drugs, over the next two years.
The company said a comprehensive layoff package would be made available to workers and that most will remain in their jobs until the end of 2022.
It has five sites in Ireland, but the other four that employ 1,400 people are not affected by this decision.
Viatris was formed through a recent merger between Mylan and Upjohn, which closed in November.
In a statement, Viatris said the decision to close the Baldoyle plant was not made lightly.
The company said it was committed to working with public officials and the community to identify appropriate potential alternatives for the site, if possible.
He added that, in the meantime, he remains committed to treating those affected fairly and with respect.
The firm said no immediate action will be taken and that the majority of its workforce will remain employed until the end of 2022.
It read, “Today’s decision in no way reflects the company’s genuine appreciation for the commitment and work ethic of the people and the Baldoyle community.
“Viatris appreciates the dedication shown on this site and its remaining workforce in Ireland will continue to play an important role in the future of the company.”
He said that following the closure of the oral solid dose manufacturing facility, it will continue to maintain a significant presence in Ireland.
The company added: “The remaining operational workforce in Ireland will continue its focus on manufacturing sterile injectables at its Galway facility, which is also home to one of the company’s injectables research and development centers; producing dry powder inhalers. at its world-class respiratory facility in Dublin; manufacture oral solid doses and other medications at its Damastown facility; and produce active pharmaceutical ingredients at its Little Island plant in Cork.
“Viatris will also maintain the company’s corporate office in Northern Cross.”
The firm said it will offer employees comprehensive severance packages, which include continuation of pay and medical care, career counseling and ongoing coverage under the Employee Assistance Program.
The Baldoyle closure is the result of a global restructuring initiative by the Pittsburgh-based firm, which aims to achieve cost savings of $ 1 billion by the end of 2024.
The company said it plans to streamline its global manufacturing and supply chain network, either by closing, downsizing or divesting up to 15 facilities.
It said these facilities are no longer viable due to overcapacity, challenging market dynamics or a shift in its product portfolio towards more complex products.
The company said that, whenever feasible, it will seek potential buyers for the facilities in order to preserve as many jobs as possible and will work with affected communities to identify appropriate potential alternatives.
“Any workforce actions that the company takes as part of this restructuring initiative will be implemented in a manner that is consistent with its longstanding commitment to treating employees fairly and with respect,” he said.
Other plants in the US, Puerto Rico, Poland and India will also be affected, with up to 20% of the 45,000 workers worldwide will be affected.
“We have been continuously committed to the company and will work over the next two years to secure alternative investments,” IDA Ireland said in a statement.
“This is part of the company’s global strategy, it is not specific to Ireland and the company’s other operations in Ireland are not affected.”
Tánaiste Leo Varadkar said the news was devastating for those who work at the company.
The Minister of Enterprise, Trade and Employment said: “The Government will make all necessary state assistance available to workers and we will work throughout the Government to help all workers find new jobs and education and training opportunities when they are make the reductions. “
[ad_2]